The liver imaging reporting and data system (LI-RADS) recently introduced a new treatment response algorithm, namely LI-RADS treatment response (LR-TR), for HCCs treated with locoregional therapy. Using pathologic tumor viability as the reference standard, our study showed that LR-TR viable category resulted in sensitivities of 67.3%/74.5% on CT and 75.5%/80.9% on Gd-EOB-MRI; and specificities of 88.6%/88.6% on CT and 80.0%/82.9% on Gd-EOB-MRI, in reviewers 1/2, respectively, which were not significantly different between CT and Gd-EOB-MRI. In addition, our modified TR criteria applying MRI ancillary features demonstrated significantly higher sensitivity (83.6%/88.2%) and comparable specificity (80.0%/77.1%) than LR-TR on CT or MRI.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords